Von Hippel-Lindau Alliance Statement: MK-6482 (PT-2977) Phase 2 Trial Results

Boston, MA – The von Hippel-Lindau Alliance enthusiastically welcomes the results of the MK-6482 (PT-2977) Phase 2 trial results, announced by Merck on May 13. The trial, for treatment of VHL disease-associated clear cell renal carcinoma, enrolled 61 VHL patients. Thirty percent of patients showed tumor shrinkage of at least 30%; 86.9% of patients had some decrease in the size of target lesions.

“On behalf of the von Hippel-Lindau (VHL) community, and the dozens of von Hippel-Lindau patients who were enrolled in the MK-6482 Phase 2 trial, we cannot begin to express the hope and excitement that this drug may mean to patients who currently have no therapeutic options available,” VHLA Executive Director Dr. Ilene Sussman.

“As we listened to the positive anecdotal feedback from VHL patients participating in the MK-6482 trial, we hardly dared take a breath,” continued Dr. Sussman. “There is still a long regulatory and testing road to travel, but MK-6482 is the first time that patients fighting this disease – which patients often describe as having cancer again, and again, and again- have the hope of a systemic therapeutic intervention.”

For further information, please refer to Merck's press release

About VHL
VHL or von Hippel-Lindau disease is a genetic form of cancer. VHL patients battle a series of tumors throughout their lives. The *VHL* gene controls the major feeding pipeline of every tumor. Curing VHL is one step closer to curing many other forms of cancer.

About the VHL Alliance
The VHL Alliance (VHLA) is the preeminent resource and clearinghouse for those affected by von Hippel-Lindau disease, including patients, caregivers, researchers, and the medical community. VHLA is a 501(c)(3) non-profit organization founded in 1993, which is dedicated to research, education, and support to improve awareness, diagnosis, treatment, and quality of life for those affected by VHL. VHLA is the leading funder of VHL research, funding over $2.3 million in grants to support studies designed to find a cure. The VHL Alliance’s vision is Curing Cancer through VHL.

*For information about VHL and the VHL Alliance, please visit vhl.org.*

###